Regeneron has won two US Food and Drug Administration (FDA) approvals for Eylea HD (aflibercept), adding another indication ...

First and only FDA-approved treatment for RVO indicated for up to every 8-week dosing after an initial monthly dosing period Monthly dosing ...

The FDA has approved Eylea HD (aflibercept) 8 mg to treat patients with macular edema following retinal vein occlusion (RVO) with dosing of up to every 8 weeks after an initial monthly dosing period.

DelveInsight's KLKB1 Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a ...

Cataract surgery is one of the most common and successful procedures for restoring clear vision. Millions of patients undergo ...

Diabetic eye damage can begin early, even before diagnosis, silently threatening vision. Early screenings and lifestyle ...

(TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the U.S. Food and Drug Administration (FDA) has approved PADCEV (R) (enfortumab vedotin-ejfv), a Nectin-4 directed ...

According to the Indonesian Health Survey, nearly 65 million people in Indonesia are suspected of having diabetes mellitus.

November is observed as Diabetic Eye Disease Awareness Month, a month dedicated to educating people about the serious eye ...

The FDA approved Eylea HD for the treatment of macular edema following retinal vein occlusion, according to a press ...

The US Food and Drug Administration (FDA) has approved aflibercept injection 8 mg (EYLEA HD) from Regeneron Pharmaceuticals ...

African marigold, popularly known as Tagetes erecta, is a vibrant flower that has been used in traditional medicine for ...